Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics
Purpose The aim of this study was to investigate factors associated with the occurrence of extrapyramidal symptoms (EPS) in users of second-generation antipsychotics (SGA). Methods Observational cross-sectional study based on a random sample of subjects from three outpatient clinics. Inclusion cr...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | article |
| Idioma: | eng |
| Publicado em: |
Springer Berlin Heidelberg
|
| Assuntos: | |
| Endereço do item: | https://repositorio.ufrn.br/jspui/handle/123456789/25430 http://dx.doi.org/10.1007/s00228-016-2166-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
| id |
ri-123456789-25430 |
|---|---|
| record_format |
dspace |
| spelling |
ri-123456789-254302021-11-11T19:14:01Z Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics Araújo, Aurigena Antunes de Ribeiro, Susana Barbosa Medeiros, Caroline Addison Xavier Chaves, Katarina Melo Alves, Maria do Socorro Costa Feitosa Oliveira, Antonio Gouveia Martins, Rand Randall Schizophrenia Second-generation antipsychotics Extrapyramidal symptoms Adjunctive therapy Purpose The aim of this study was to investigate factors associated with the occurrence of extrapyramidal symptoms (EPS) in users of second-generation antipsychotics (SGA). Methods Observational cross-sectional study based on a random sample of subjects from three outpatient clinics. Inclusion criteria were age between 18 and 65 years, of both genders, with a diagnosis of schizophrenia and under the use of a single SGA agent. Subjects who had received i.m. long-acting antipsychotics in the past were excluded. The families of eligible patients were contacted by phone and, if willing to participate in the study, a household visit was scheduled. Informed consent was obtained from all study subjects and their next of kin. The risk of EPS associated with sociodemographic, clinical features and medications used was analyzed by logistic regression. Results The study population consisted of 213 subjects. EPS were observed in 38.0% of subjects. The more commonly used SGA were olanzapine (76, 35.7%), risperidone (74, 34.3%), quetiapine (26, 12.2%), and ziprasidone (23, 10.8%). Among the drugs used as adjunctive therapy for schizophrenia, benzodiazepines were the most prevalent (31.5%), followed by carbamazepine (24.4%) and antidepressants (20.2%). Multivariate analysis showed that the risk of EPS was associated with the use of carbamazepine (odds ratio 3.677, 95% CI 1.627–8.310). We found no evidence that the type of SGA modified the risk of EPS. Conclusion The occurrence of EPS in SGA users is a common finding, with no difference of antipsychotics studied in relation to the risk of extrapyramidal manifestations. The adjunctive use of carbamazepine may predispose the user of SGA to the occurrence of EPS. 2018-06-16T12:50:43Z 2018-06-16T12:50:43Z 2016-11-26 article ARAÚJO, Aurigena Antunes de et al. Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics. European Journal of Clinical Pharmacology, v. 73, p. 351-355, 2016. Disponível em: <https://link.springer.com/article/10.1007/s00228-016-2166-2>. Acesso em: 20 mar. 2018. 1432-1041 https://repositorio.ufrn.br/jspui/handle/123456789/25430 http://dx.doi.org/10.1007/s00228-016-2166-2 eng Acesso Aberto application/pdf Springer Berlin Heidelberg |
| institution |
Repositório Institucional |
| collection |
RI - UFRN |
| language |
eng |
| topic |
Schizophrenia Second-generation antipsychotics Extrapyramidal symptoms Adjunctive therapy |
| spellingShingle |
Schizophrenia Second-generation antipsychotics Extrapyramidal symptoms Adjunctive therapy Araújo, Aurigena Antunes de Ribeiro, Susana Barbosa Medeiros, Caroline Addison Xavier Chaves, Katarina Melo Alves, Maria do Socorro Costa Feitosa Oliveira, Antonio Gouveia Martins, Rand Randall Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
| description |
Purpose
The aim of this study was to investigate factors associated with the occurrence of extrapyramidal symptoms (EPS) in users of second-generation antipsychotics (SGA).
Methods
Observational cross-sectional study based on a random sample of subjects from three outpatient clinics. Inclusion criteria were age between 18 and 65 years, of both genders, with a diagnosis of schizophrenia and under the use of a single SGA agent. Subjects who had received i.m. long-acting antipsychotics in the past were excluded. The families of eligible patients were contacted by phone and, if willing to participate in the study, a household visit was scheduled. Informed consent was obtained from all study subjects and their next of kin. The risk of EPS associated with sociodemographic, clinical features and medications used was analyzed by logistic regression.
Results
The study population consisted of 213 subjects. EPS were observed in 38.0% of subjects. The more commonly used SGA were olanzapine (76, 35.7%), risperidone (74, 34.3%), quetiapine (26, 12.2%), and ziprasidone (23, 10.8%). Among the drugs used as adjunctive therapy for schizophrenia, benzodiazepines were the most prevalent (31.5%), followed by carbamazepine (24.4%) and antidepressants (20.2%). Multivariate analysis showed that the risk of EPS was associated with the use of carbamazepine (odds ratio 3.677, 95% CI 1.627–8.310). We found no evidence that the type of SGA modified the risk of EPS.
Conclusion
The occurrence of EPS in SGA users is a common finding, with no difference of antipsychotics studied in relation to the risk of extrapyramidal manifestations. The adjunctive use of carbamazepine may predispose the user of SGA to the occurrence of EPS. |
| format |
article |
| author |
Araújo, Aurigena Antunes de Ribeiro, Susana Barbosa Medeiros, Caroline Addison Xavier Chaves, Katarina Melo Alves, Maria do Socorro Costa Feitosa Oliveira, Antonio Gouveia Martins, Rand Randall |
| author_facet |
Araújo, Aurigena Antunes de Ribeiro, Susana Barbosa Medeiros, Caroline Addison Xavier Chaves, Katarina Melo Alves, Maria do Socorro Costa Feitosa Oliveira, Antonio Gouveia Martins, Rand Randall |
| author_sort |
Araújo, Aurigena Antunes de |
| title |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
| title_short |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
| title_full |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
| title_fullStr |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
| title_full_unstemmed |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
| title_sort |
factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
| publisher |
Springer Berlin Heidelberg |
| publishDate |
2018 |
| url |
https://repositorio.ufrn.br/jspui/handle/123456789/25430 http://dx.doi.org/10.1007/s00228-016-2166-2 |
| work_keys_str_mv |
AT araujoaurigenaantunesde factorsassociatedwithexpressionofextrapyramidalsymptomsinusersofatypicalantipsychotics AT ribeirosusanabarbosa factorsassociatedwithexpressionofextrapyramidalsymptomsinusersofatypicalantipsychotics AT medeiroscarolineaddisonxavier factorsassociatedwithexpressionofextrapyramidalsymptomsinusersofatypicalantipsychotics AT chaveskatarinamelo factorsassociatedwithexpressionofextrapyramidalsymptomsinusersofatypicalantipsychotics AT alvesmariadosocorrocostafeitosa factorsassociatedwithexpressionofextrapyramidalsymptomsinusersofatypicalantipsychotics AT oliveiraantoniogouveia factorsassociatedwithexpressionofextrapyramidalsymptomsinusersofatypicalantipsychotics AT martinsrandrandall factorsassociatedwithexpressionofextrapyramidalsymptomsinusersofatypicalantipsychotics |
| _version_ |
1773959182454620160 |